13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001842545
Total reported value
$603.3M
$603.3M
27 檔
42.1%
In Q1 2026, Eagle Health Investments LP's U.S. equity holdings reached a combined market value of $603.3M, distributed across 27 disclosed stock positions.
In Q1 2026, Eagle Health Investments LP displayed an active expansion posture, initiating 7 new positions and adding to 16 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | XBI | Ss Spdr S&p Biotech ETF | ETF-Tech | 16.31% | -16.31% | EXIT | |
| 2 | ARGX | Argenx Se - Adr | Stock-Healthcare | 9.75% | +2.00% | +21.69% | |
| 3 | ICLR | ICON Public Limited Company | Stock-Healthcare | 6.94% | +1.93% | +45.09% | |
| 4 | INSM | Insmed Inc | Stock-Healthcare | 6.41% | +0.38% | +6.34% | |
| 5 | GH | Guardant Health Inc | Stock-Healthcare | 5.01% | +2.47% | +9.22% | |
| 6 | BMRN | Biomarin Pharmaceutical Inc | Stock-Healthcare | 5.00% | +0.92% | +37.89% | |
| 7 | NTRA | Natera Inc | Stock-Healthcare | 4.26% | -3.55% | -33.50% | |
| 8 | SRRK | Scholar Rock Holding CORP | Stock-Other | 4.25% | +0.81% | +35.98% | |
| 9 | ILMN | Illumina Inc | Stock-Healthcare | 4.04% | +1.42% | -18.93% | |
| 10 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 3.80% | -3.80% | EXIT | |
| 11 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 3.47% | -3.47% | EXIT | |
| 12 | ASND | Ascendis Pharma A/S | Stock-Other | 3.47% | -3.47% | EXIT | |
| 13 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 3.31% | +1.74% | +212.95% | |
| 14 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 3.24% | +1.65% | — | |
| 15 | BSX | Boston Scientific CORP | Stock-Healthcare | 3.22% | -0.61% | — | |
| 16 | PRCT | Procept Biorobotics CORP | Stock-Other | 2.51% | -2.51% | EXIT | |
| 17 | FTRE | Fortrea Holdings Inc | Stock-Healthcare | 2.15% | +1.26% | +7.30% | |
| 18 | KYMR | Kymera Therapeutics Inc | Stock-Other | 2.12% | +1.04% | +6.98% | |
| 19 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 2.03% | +1.71% | +3.08% | |
| 20 | TEM | Tempus Ai Inc-cl A | Stock-Healthcare | 2.03% | +0.43% | — | |
| 21 | CMPS | Compass Pathways PLC | Stock-Other | 1.99% | +2.84% | +35.61% | |
| 22 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 1.49% | -1.49% | EXIT | |
| 23 | ALKS | Alkermes plc | Stock-Healthcare | 1.48% | +1.10% | +191.78% | |
| 24 | ATAI | Ataibeckley Inc | Stock-Other | 1.06% | +0.43% | — | |
| 25 | ISRG | Intuitive Surgical Inc | Stock-Healthcare | 0.35% | -0.06% | — | |
| 26 | IMCR | Immunocore Holdings Plc-adr | Stock-Other | 0.24% | — | — | |
| 27 | ✓ | Stock-Other | 0.07% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | PTGX | Protagonist Therapeutics Inc | +2.2% | +212.95% | Add |
| 2 | 430 | Terns Pharmaceuticals Inc | +1.4% | +49.95% | Add |
| 3 | ALKS | Alkermes plc | +1% | +191.78% | Add |
| 4 | 260 | Centessa Pharmaceuticals-adr | +0.9% | +107.85% | Add |
| 5 | SRRK | Scholar Rock Holding CORP | +0.7% | +35.98% | Add |
| 6 | PRCT | Procept Biorobotics CORP | +0.4% | +86.04% | Add |
| 7 | BMRN | Biomarin Pharmaceutical Inc | +0.2% | +37.89% | Add |
| 8 | RVMD | Revolution Medicines Inc | — | +3.08% | Add |
| 9 | IMCR | Immunocore Holdings Plc-adr | -0.1% | — | Unchanged |
| 10 | ISRG | Intuitive Surgical Inc | -0.2% | — | Unchanged |
| 11 | KYMR | Kymera Therapeutics Inc | -0.2% | +6.98% | Add |
| 12 | CMPS | Compass Pathways PLC | -0.3% | +35.61% | Add |
| 13 | BBIO | Bridgebio Pharma Inc | -0.9% | +2.98% | Add |
| 14 | GH | Guardant Health Inc | -1.4% | +9.22% | Add |
| 15 | INSM | Insmed Inc | -1.7% | +6.34% | Add |
| 16 | ARGX | Argenx Se - Adr | -1.8% | +21.69% | Add |
| 17 | FTRE | Fortrea Holdings Inc | -2.5% | +7.30% | Add |
| 18 | ILMN | Illumina Inc | -2.6% | -18.93% | Trim |
| 19 | ICLR | ICON Public Limited Company | -3% | +45.09% | Add |
| 20 | NTRA | Natera Inc | -5% | -33.50% | Trim |
| 21 | XBI | Ss Spdr S&p Biotech ETF | — | NEW | New buy |
| 22 | NBIX | Neurocrine Biosciences Inc | — | EXIT | Sold out |
| 23 | ASND | Ascendis Pharma A/S | — | NEW | New buy |
| 24 | RARE | Ultragenyx Pharmaceutical In | — | NEW | New buy |
| 25 | BSX | Boston Scientific CORP | — | NEW | New buy |
| 26 | EXK | Exact Sciences CORP | — | EXIT | Sold out |
| 27 | TEM | Tempus Ai Inc-cl A | — | NEW | New buy |
| 28 | LEGN | Legend Biotech Corp-adr | — | EXIT | Sold out |
| 29 | ATAI | AtaiBeckley Inc. | — | EXIT | Sold out |
| 30 | SLNOEUR | Soleno Therapeutics Inc | — | EXIT | Sold out |
| 31 | ATAI | Ataibeckley Inc | — | NEW | New buy |
| 32 | QURE | uniQure N.V. | — | EXIT | Sold out |
| 33 | PRAX | Praxis Precision Medicines I | — | EXIT | Sold out |
| 34 | MLTX | Moonlake Immunotherapeutics | — | EXIT | Sold out |
| 35 | IRON | Disc Medicine Inc | — | EXIT | Sold out |
| 36 | VIR | Vir Biotechnology Inc | — | EXIT | Sold out |
| 37 | ✓ | — | NEW | New buy |
According to official SEC Form 13F filings, Eagle Health Investments LP reported a total U.S. public equity portfolio value of $603.3M across 27 disclosed positions in Q1 2026.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including XBI, ARGX, ICLR) accounted for 42.1% of total reported equity market value during Q1 2026.
Top New Position Initiated
XBI
市值: $93.2M
Top Position Liquidated / Trimmed
NBIX
前期市值: $23.1M
During Q1 2026, Eagle Health Investments LP's top holdings by market value included XBI (16.3%)、ARGX (9.8%)、ICLR (6.9%). The largest single position, XBI, represented 16.3% of total portfolio value.
In Q1 2026, Eagle Health Investments LP made 35 total portfolio adjustments, initiating 7 new buys, adding to 16 positions, trimming 2 holdings, and fully liquidating 10 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.